AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01905371 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physical Therapy
Description: One hour of active physical therapy (PT) directed at a primary motor impairment. An outline indicating a range and level of physical therapy interventions will be provided to the therapists, and the level and of therapy will be recorded.
Study NCT01905371 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03323983 — intervention group
Intervention type: OTHER
Intervention: data collection
Description: data collection
Study NCT02243436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab Vedotin
Description: Brentuximab Vedotin, 0.9mg/kg, 1.2mg/kg, 1.8mg/kg, day 1
Study NCT02243436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Intravenose use, 40mg/m2/day, on days 1 to 4
Study NCT02243436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Soludomerin
Description: Intravenous use, 250mg/day, on days 1 to 4
Study NCT02243436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenous use, 25mg/m2/day, on days 1 to 4
Study NCT02243436 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ara C
Description: Intravenous use, 2g/m2, day 5
Study NCT03729999 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Portable, Point-of-Care Ultrasound
Description: Portable ultrasonography done at the bedside.
Study NCT03715738 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: arm 1 : Creaform3D + MyotonPRO
Description: After inclusion,are carried out:~* estimation of the volume of the breast to be reduced with the 3D digital camera~* measurement of breast density by Likert scale and MyotonPRO~The volumetric measurement of the breast is performed using the 3D digital camera. The patient is bent forward with hands resting on a chair to be as still as possible over a period of 30 seconds to 1 minute. The 3D digital camera rotates around the breast to capture the volume of the breast.~In peroperative, the weight of tissues removed is weighed (in grams). The removed weight is recorded in the observation notebook.~In postoperative (4 months), the possible long-term complications related to the intervention (mainly the dissatisfaction of the patient as for the aesthetic result) are collected then a new acquisition of the mammary volume is carried out with the digital camera 3D.~Once this measurement is completed, participation in the study is complete.
Study NCT01083407 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.12% Chlorhexidine Digluconate
Description: Oral care with 0.12% Chlorhexidine Digluconate and toothbrushing is realized twice a day and took about 10 minutes to complete, depending on the child's acceptance and clinical conditions.
Study NCT01083407 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Toothbrushing
Description: Gel is applied on a toothbrush, and the teeth are cleaned in quadrants; all teeth surfaces are cleaned (vestibular, lingual, occlusal, and incisal). After each quadrant is cleaned, 10 mL of water (dispensed via a syringe) is used to rinse the quadrant and continual aspiration is used to remove all the gel and debris. After all the teeth are cleaned, the ventral surface of the tongue is brushed with posteriorto-anterior movements.
Study NCT04526704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pexidartinib
Description: 200 mg capsules administered orally twice daily on an empty stomach (at least 1 hour before or at least 2 hours after a meal or snack)
Study NCT03765918 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg
Description: 200 mg administered by intravenous (IV) infusion on Day 1 of each 21-day cycle
Study NCT03765918 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 60 Gray/day
Description: Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.
Study NCT03765918 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 60 Gray/day
Description: Low risk participants administered 2 Gray/day in 30 fractions. Administered using intensity modulated radiation therapy.
Study NCT03765918 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 66 Gray/day
Description: High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.
Study NCT03765918 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 66 Gray/day
Description: High risk participants administered 2 Gray/day in 33 fractions. Administered using intensity modulated radiation therapy.
Study NCT03765918 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy 70 Gray/day
Description: Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.
Study NCT03765918 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy 70 Gray/day
Description: Participants with gross residual disease administered 2 Gray/day in 35 fractions. Administered using intensity modulated radiation therapy.
Study NCT03765918 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin 100 mg/m^2
Description: 100 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle
Study NCT03765918 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin 100 mg/m^2
Description: 100 mg/m\^2 administered by IV infusion on Day 1 of each 21-day cycle
Study NCT03468218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib
Description: Given PO
Study NCT03468218 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT01276509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PF-00547659 SC injection
Description: Placebo delivered SC, 3 doses separated by 4 weeks
Study NCT01276509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC injection
Description: Drug dose level 1 delivered SC, 3 doses separated by 4 weeks
Study NCT02546661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD4547
Description: AZD4547 Monotherapy vs. MEDI4736 (durvalumab) + AZD4547 1:1 Randomization.
Study NCT02546661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI4736
Description: MEDI4736
Study NCT01276509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC injection
Description: Drug dose level 2 delivered SC, 3 doses separated by 4 weeks
Study NCT01276509 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00547659 SC injection
Description: Drug dose level 3 delivered SC, 3 doses separated by 4 weeks
Study NCT03390270 — intervention group
Intervention type: OTHER
Intervention: Admission with NSTEMI
Description: All patients admitted to Duke University Hospital with an NSTEMI
Study NCT04411810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nevisense 3.0
Description: Nevisense, an AI-based point-of-care system for the non-invasive evaluation of irregular moles remains the only FDA approved system available for melanoma detection in the US. Nevisense 3.0 will be used as a one-time exposure of \<8 seconds per lesion. Disposable electrodes that contact the participant are 5mm x 5mm in size. Nevisense 3.0 measures electrical impedance of skin lesions and provides an output called the electrical impedence spectroscopy (EIS) score. Electrical impedance is a measure of a material's overall resistance to the flow of alternating electric currents of various frequencies. The principle is that electrical impedance is different in normal versus abnormal tissue.
Study NCT04411810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dermlite Cam
Description: Dermlite Cam is a digital camera that captures images of the skin under cross-polarized and non-polarized light and is 510(k) exempt. The DermLite Cam device appears as a single piece camera with a charging cable and USB computer cable. As part of the camera unit, an extensor arm exists to allow for the capture of standardized clinical images. The DermLite Cam will be used to acquire 3 images of \<5 seconds per lesion (one clinical, one polarized dermoscopic, and one non-polarized dermoscopic). NOTE - for the purposes of this study, teledermatology images (dermoscopic and clinical - at approximately 6 inches, 12 inches, and 18 inches) were taken using the Barco Demetra after technical issues arose that prohibited the continued use of the Dermlite Cam.
Study NCT04411810 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: A skin biopsy is a small procedure that removes a sample of skin from the surface of the body. The method utilized will be either a shave or punch technique. The maximum size of a punch biopsy will be 6mm and these wounds are generally closed with no more than 2-3 sutures. A skin biopsy takes \<15 minutes including preparation time, administration of intradermal anesthesia using lidocaine 1% with epinephrine 1:100,000, removal of the skin sample, achievement of hemostasis, dressing the wound, and providing instructions for home care. Samples will be placed formalin for routine processing.
Study NCT04411810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Barco Demetra
Description: Barco Demetra is a non-invasive skin imaging system, which acquires multispectral and white light dermoscopic images and clinical photographs of the skin which can then be stored, retrieved, displayed, and reviewed by medical practitioners. The Barco Demetra received 510(k) Premarket approval (K192829). The system involves a hardware imaging device and a stand-alone software application. The hardware device is a portable, battery-powered medical device for acquiring and visualizing images of the skin and uploads all images to cloud storage. The software application is cloud software with an associated web application; it can be used to visualize images and related data and can generate consultation reports. For the purposes of this study, teledermatology images (dermoscopic and clinical - at approximately 6 inches, 12 inches, and 18 inches) were taken using the Barco Demetra after technical issues arose that prohibited the continued use of the Dermlite Cam.
Study NCT03685253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Niagen
Description: Niagen® (3-(Aminocarbonyl)-1-β-D-ribofuranosyl-pyridinium chloride - NR) will be the experimental treatment, at a dose of 1000 mg/day taken as two 250 mg capsules twice daily for 6 months.
Study NCT02546661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib
Description: MEDI4736 (durvalumab) + Olaparib
Study NCT02546661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1775
Description: MEDI4736 (durvalumab) + AZD1775
Study NCT02546661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vistusertib
Description: MEDI4736 (durvalumab) + Vistusertib
Study NCT02546661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9150
Description: MEDI4736 (durvalumab) + AZD9150
Study NCT02546661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: MEDI4736 (durvalumab) + Selumetinib
Study NCT03524183 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Fitness Buddy Ecosystem
Description: The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.
Study NCT03524183 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Fitness Buddy Ecosystem
Description: The Virtual Fitness Buddy Ecosystem allows parents to stay involved in the intervention and support their children's PA efforts even when they cannot be with their children. A virtual pet, designed to mimic human-pet relationships in the physical world, will guide children to set and meet PA goals and offer tailored support. In collaboration with YMCA, 480 children and 480 parents in 24 afterschool programs will be randomly assigned to treatment and control groups. Afterschool programs in the treatment group will receive the Ecosystem intervention for 6-months; afterschool programs in the control group will not experience the Ecosystem. All children will complete baseline assessments, a 3-month posttest, and a 6-month and 12-month follow up. Parents and children will provide self-report data on their perceived social support, motivation, and PA self-efficacy. PA will be assessed with activity monitors, which children will wear throughout the project.
Study NCT04420221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sa-5Ag half dose non-adjuvanted
Description: 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, non-adjuvanted at Day 1, administered intramuscularly.
Study NCT04420221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sa-5Ag full dose non-adjuvanted
Description: 1 dose of Sa-5Ag (5 antigens of S. aureus) full dose, non-adjuvanted at Day 1, administered intramuscularly.
Study NCT04420221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sa-5Ag half dose adjuvanted
Description: 1 dose of Sa-5Ag (5 antigens of S. aureus) half dose, adjuvanted at Day 1, administered intramuscularly.
Study NCT04420221 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sa-5Ag full dose adjuvanted
Description: A series of 2 doses of S. aureus candidate vaccine (Sa-5Ag full dose adjuvanted) given approximately 2 months apart (Days 1 and 61), administered intramuscularly.
Study NCT04420221 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: One dose of placebo (saline solution for injection/ vial or prefilled syringe) at Day 1 for placebo groups 1 to 3 and a series of 2 doses of placebo given approximately 2 months apart (Days 1 and 61) for placebo groups 4 and 5, administered intramuscularly.
Study NCT02923180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoblituzumab
Description: Enoblituzumab 15mg/kg IV (in the vein) weekly for 6 doses beginning 50 days prior to radical prostatectomy.
Study NCT04293055 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Maintenance program
Description: 1-year weight loss maintenance program, consisting of monthly newsletters
Study NCT01904253 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS-102
Description: 35 mg/m2/dose, orally, twice daily on days 1-5 and 8-12 of each 28-day cycle. Number of cycles: until at least one of the discontinuation criteria is met.
Study NCT01904253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amrubicin (Japan)
Description: Patients will receive treatment administered according to the country-specific approved prescribing information
Study NCT01904253 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan (Japan/Europe)
Description: Patients will receive treatment administered according to the country-specific approved prescribing information
Study NCT03603223 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT00489489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Description: Film-coated tablet~Oral administration
Study NCT00489489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Teriflunomide)
Description: Film-coated tablet~Oral administration
Study NCT00489489 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Interferon-β
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
Study NCT04293055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Maintenance program
Description: 1-year weight loss maintenance program, consisting of monthly newsletters
Study NCT04293055 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Phone coaching
Description: Some individuals will receive 4 consecutive weeks of phone coaching. The first coaching call will be approximately 30 minutes in duration and follow-up calls will be 10-15 minutes in duration. Coaches will help support participants in their weight loss maintenance efforts. Once coaching calls are completed, the participant will not have any other contact with their coach.
Study NCT03641313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berzosertib
Description: Given IV
Study NCT03641313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography Assisted Biopsy
Description: Undergo CT assisted biopsy
Study NCT03641313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic Biopsy
Description: Undergo endoscopic biopsy
Study NCT03641313 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Given IV
Study NCT03641313 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT01336010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2a
Description: PEG-IFN 180 mcg in 0.5 ml (prefilled syringes) administered subcutaneously (SC) once weekly
Study NCT01336010 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: Genotype 1: 1000mg or 1200mg p.o. daily in split doses (1000mg for patients weighing \<75kg and 1200mg for patients weighing ≥ 75kg) Genotypes 2/3: 800mg daily p.o. daily in split doses for genotype 2 and 3 patients
Study NCT01715805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cariprazine
Description: Cariprazine capsules 1.5 to 4.5 mg/day
Study NCT01715805 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Placebo
Description: Dose-matched placebo capsule once per day
Study NCT00489489 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-β
Description: Powder for reconstitution, of any licensed strength for either intramuscular or subcutaneous injection
Study NCT01715805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Dose-matched placebo capsule once per day
Study NCT01715805 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antidepressant Therapy (ADT)
Description: ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
Study NCT03741608 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: High blood pressure management education
Description: The 7-part education series includes 5 sessions focused on mindfulness and breathing techniques for stress reduction. One session will focus on choosing healthy, low salt foods and will provide resources for smoking cessation. The final session will include a grocery store tour to teach participants how to read food labels and to purchase healthy food.
Study NCT01715805 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Antidepressant Therapy (ADT)
Description: ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
Study NCT01715805 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Antidepressant Therapy (ADT)
Description: ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
Study NCT03913611 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Accelerated rehabilitation protocol
Description: Patients in this group will undergo an accelerated rehabilitation protocol, without movement restrictions. Movement restriction will instead be governed by patient comfort.
Study NCT03913611 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Traditional rehabilitation protocol
Description: Patients in this group will undergo a traditional rehabilitation protocol, with movement restrictions and sling use for 6 weeks following surgery.
Study NCT01673932 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: UCBMC
Description: Transplant 10-40 million viable UCBMC suspension into brain adjacent to the infracted site
Study NCT01673932 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgery
Study NCT02392429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study NCT02392429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Aspiration
Description: Undergo bone marrow biopsy and aspiration
Study NCT02392429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bone Marrow Biopsy
Description: Undergo bone marrow biopsy and aspiration
Study NCT02392429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Given anthracycline IV
Study NCT02392429 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo FLT PET/CT
Study NCT02392429 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV